Mystic Asset Management Inc. Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Mystic Asset Management Inc. acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,284 shares of the pharmaceutical company’s stock, valued at approximately $638,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in VRTX. Bangor Savings Bank increased its holdings in shares of Vertex Pharmaceuticals by 0.4% in the 2nd quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company’s stock worth $2,220,000 after purchasing an additional 20 shares in the last quarter. Confluence Wealth Services Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 4.0% during the fourth quarter. Confluence Wealth Services Inc. now owns 545 shares of the pharmaceutical company’s stock valued at $247,000 after purchasing an additional 21 shares in the last quarter. Trust Point Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 2.7% during the second quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company’s stock valued at $394,000 after purchasing an additional 21 shares in the last quarter. Williams Jones Wealth Management LLC. boosted its position in shares of Vertex Pharmaceuticals by 1.9% during the fourth quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company’s stock valued at $524,000 after buying an additional 21 shares during the last quarter. Finally, Cannell & Spears LLC boosted its position in shares of Vertex Pharmaceuticals by 1.2% during the first quarter. Cannell & Spears LLC now owns 1,983 shares of the pharmaceutical company’s stock valued at $885,000 after buying an additional 23 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $540.26 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $374.17 and a fifty-two week high of $553.69. The company has a market cap of $137.12 billion, a P/E ratio of 31.45, a P/E/G ratio of 2.28 and a beta of 0.30. The business’s 50 day moving average price is $490.59 and its 200-day moving average price is $465.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). The firm had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.23 billion. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%.Vertex Pharmaceuticals’s revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the business posted $4.52 EPS. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 16.86 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on VRTX. Barclays boosted their target price on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Cantor Fitzgerald lifted their target price on Vertex Pharmaceuticals from $590.00 to $595.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Royal Bank Of Canada lifted their price target on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Stifel Nicolaus set a $500.00 price objective on Vertex Pharmaceuticals in a research note on Tuesday, August 4th. Finally, Truist Financial lifted their target price on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $563.50.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex completed the Phase 2b trial of inaxaplin, its treatment candidate for APOL1-mediated kidney disease. The milestone advances a potentially important non-cystic-fibrosis growth driver and could support future regulatory and commercialization plans. Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial
• Positive Sentiment: Wall Street remains optimistic about VRTX, with BMO Capital reiterating a Buy rating. Analysts point to Vertex’s leadership in cystic fibrosis and potential contributions from newer products and pipeline programs. Vertex Pharmaceuticals Receives a Buy from BMO Capital
• Positive Sentiment: Recent commentary describes cystic fibrosis as a continuing “engine” for Vertex’s rally, suggesting investors expect durable cash generation and additional growth from the company’s dominant franchise. Vertex Pharmaceuticals’ Rally Has a New Engine — and Wall Street Thinks the Best Is Still Ahead
• Neutral Sentiment: Vertex is reportedly entering a new healthcare focus, indicating a broader strategic emphasis beyond its established cystic fibrosis business. The longer-term impact will depend on the specific programs, investment requirements, and commercial potential. Vertex Pharmaceuticals Enters New Healthcare Focus
• Negative Sentiment: Shareholder challenges to Vertex’s proposed acquisition of Crinetics Pharmaceuticals create execution and deal-completion risk. Delays, litigation, or a higher acquisition cost could weigh on sentiment, even though the transaction is intended to expand Vertex’s pipeline. Crinetics Faces Shareholder Challenges to Vertex Merger Deal

Insider Activity at Vertex Pharmaceuticals

In other news, CMO Carmen Bozic sold 4,062 shares of Vertex Pharmaceuticals stock in a transaction on Monday, June 15th. The stock was sold at an average price of $450.00, for a total transaction of $1,827,900.00. Following the completion of the sale, the chief marketing officer directly owned 16,953 shares in the company, valued at approximately $7,628,850. This trade represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total transaction of $787,485.00. Following the sale, the executive vice president directly owned 45,321 shares of the company’s stock, valued at $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 10,464 shares of company stock worth $4,959,397 in the last quarter. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.